MedTrace Logo

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

NCT06210243 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2025-02-18

No results posted yet for this study

Summary

It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.

Conditions

  • Lymphoma, B-Cell
  • CAR-T

Interventions

BIOLOGICAL

C752

C752 will be administered on Day 0

Sponsors & Collaborators

  • Shanghai PerHum Therapeutics Co., Ltd.

    collaborator INDUSTRY

  • 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

    lead OTHER

Principal Investigators

  • Sanbin Wang, M.D. · 920th Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-24
Primary Completion
2024-12-24
Completion
2024-12-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06210243 on ClinicalTrials.gov